- Conditions
- Type1 Diabetes Mellitus
- Interventions
- Dapagliflozin 5mg, Placebo Oral Tablet
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- La Jolla, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 188
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes
- Interventions
- Dapagliflozin, Placebo-matching dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 2,996 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 164
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Ozark, Alabama + 124 more
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Heart Failure
- Interventions
- Dapagliflozin 10mg Tab
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Diabetic Kidney Disease
- Interventions
- MEDI3506, Placebo, Dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 101 Years
- Enrollment
- 609 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 42 more
- Conditions
- Weight Loss
- Interventions
- Dapagliflozin Tablet, Placebo Tablet
- Drug
- Lead sponsor
- Christopher Bell
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Fort Collins, Colorado
- Conditions
- Type 2 Diabetes
- Interventions
- dapagliflozin, placebo, metformin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 389 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 111
- States / cities
- Bayou La Batre, Alabama • Birmingham, Alabama • Huntsville, Alabama + 107 more
- Conditions
- Type 2 Diabetes
- Interventions
- Dapagliflozin, Placebo, Metformin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 77 Years
- Enrollment
- 915 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 28
- States / cities
- Tempe, Arizona • Encino, California • Fresno, California + 24 more
- Conditions
- Type 2 Diabetes Mellitus, Myocardial Fibrosis, Myocardial Inflammation
- Interventions
- dapagliflozin, Placebo
- Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- simvastatin, Dapagliflozin, valsartan
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Neptune City, New Jersey
- Conditions
- Breast Cancer
- Interventions
- Alpelisib, Fulvestrant, Metformin XR, Dapagliflozin + metformin XR, Dapagliflozin
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Pancreas Cancer, Pancreatic Cancer, Cancer of the Pancreas
- Interventions
- Dapagliflozin, BIOSENSE meters
- Drug · Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Acute Kidney Injury, Percutaneous Coronary Intervention
- Interventions
- Dapagliflozin 10mg Tab
- Drug
- Lead sponsor
- Albert Einstein Healthcare Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Heart Failure, Diabetes
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • New Orleans, Louisiana • Philadelphia, Pennsylvania
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Dapagliflozin, Metformin XR, dapagliflozin matching Placebo, metformin HCl Modified Release matching Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 77 Years
- Enrollment
- 1,093 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 64
- States / cities
- Ozark, Alabama • Tempe, Arizona • Concord, California + 53 more
- Conditions
- Heart Failure, Chronic Kidney Disease
- Interventions
- AZD9977, Dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 21 Years to 130 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 26
- States / cities
- Beverly Hills, California • Fountain Valley, California • Northridge, California + 22 more
- Conditions
- Weight Loss
- Interventions
- Dapagliflozin, Placebo, Weight maintenance, Ad libitum dietary intake, Dietary restriction
- Drug · Behavioral
- Lead sponsor
- Christopher Bell
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Fort Collins, Colorado
- Conditions
- Cystinuria
- Interventions
- Dapagliflozin
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 35 Years to 70 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 3
- States / cities
- San Diego, California • Baton Rouge, Louisiana • Philadelphia, Pennsylvania
- Conditions
- Chronic Heart Failure With Reduced Systolic Function
- Interventions
- Dapagliflozin, Dapagliflozin matching placebo
- Drug
- Lead sponsor
- Saint Luke's Health System
- Other
- Eligibility
- 19 Years to 119 Years
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 25
- States / cities
- Fairhope, Alabama • Los Angeles, California • Jacksonville, Florida + 20 more
- Conditions
- Type 2 Diabetes
- Interventions
- Dapagliflozin, Placebo matching with Dapagliflozin, Saxagliptin, Metformin immediate release (IR)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 21 more
- Conditions
- Metastatic Breast Cancer, HER2-negative Breast Cancer
- Interventions
- Dapagliflozin 10Mg Tab
- Drug
- Lead sponsor
- Saint Luke's Health System
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Diabetes Prevention in Women After GDM Who Are at High-risk
- Interventions
- DAPA/MET XR, DAPA, MET XR
- Drug
- Lead sponsor
- Woman's
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Heart Attack, Enlarged Heart
- Interventions
- SGLT-2 inhibitors, Placebo
- Drug
- Lead sponsor
- Minneapolis Heart Institute Foundation
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota